Investor Presentaiton
Novo Nordisk Annual Report 2023
Introducing Novo Nordisk Strategic Aspirations Risks
Management
Consolidated statements
Additional information
OWNERSHIP STRUCTURE¹
Novo Nordisk
Foundation
Institutional and
private investors
100%
Novo Holding A/S
77.1%
of votes
28.1%
22.9%
71.9%
of capital
of votes
of capital
A shares
1,075m shares
23.8% of capital and
75.8% of votes
Novo Nordisk A/S
B shares
3,435m shares
76.2% of capital and
24.2% of votes
Unless required by law, Novo Nordisk has no duty and undertakes
no obligation to update or revise any forward-looking statement after
the distribution of this Annual Report 2023, whether as a result of new
information, future events, or otherwise.
Shares and capital structure
Through open and proactive communication, Novo Nordisk aims to
provide the basis for fair and efficient pricing of our shares.
Share capital and ownership
Novo Nordisk's share capital of DKK 451 million is divided into A and B share
capital. The A and B shares are calculated in units of DKK 0.10, amounting
to 4.51 billion shares. The A share capital, consisting of 1,075 million shares,
has a nominal value of DKK 107,487,200 and the B share capital, consisting
of 3,435 million shares, has a nominal value of DKK 343,512,800. Each A
share of a nominal value of DKK 0.10 carries 100 votes and each B share of
a nominal value of DKK 0.10 carries 10 votes. Novo Nordisk's B shares are
listed on Nasdaq Copenhagen and on the New York Stock Exchange (NYSE)
as American Depository Receipts (ADRs).
The general meeting has authorised the Board of Directors to distribute
extraordinary dividends, issue new shares in accordance with the Articles
of Association and repurchase shares in accordance with authorizations
granted.
The company's A shares are not listed and are held by Novo Holdings A/S²,
a Danish public limited liability company wholly owned by the Novo
Nordisk Foundation. According to the Articles of Association of the
Foundation, the A shares cannot be divested. Special rights attached to
A shares include pre-emptive subscription rights in the event of an
increase in the A share capital and pre-emptive purchase rights in the
event of a sale of A shares, while B shares take priority for liquidation
proceedings. A shares take priority for dividends below 0.5%, and B
shares take priority for dividends between 0.5 and 5%. However, in
practice, A and B shares receive the same amount of dividend per share.
As of 31 December 2023, Novo Holdings A/S held a B share capital of
a nominal value of DKK 19,018,300. Together with the A shares, Novo
Holdings A/S's total ownership amounted to a nominal value of
DKK 126,505,500. Novo Holdings A/S ownership is reflected in the
'Ownership structure' chart.
There is no complete record of all shareholders; however, based on
available sources of information, as of 31 December 2023 it is estimated
that shares were geographically distributed as shown in the 'Geographical
split of shareholders' chart. As of 31 December 2023, the free float of
listed B shares was 92.96% (of which approximately 12.18% are listed as
ADRs), excluding Novo Holdings A/S and Novo Nordisk's holding of shares.
As of 31 December 2023, Novo Holdings A/S and Novo Nordisk's holding
of B shares equaled 241,895,054 shares and had a nominal value of DKK
24,189,505. For details about the share capital, see note 4.2 to the
consolidated financial statements.
GEOGRAPHICAL SPLIT OF SHAREHOLDERS³ (% of share capital)
Denmark
North America
UK
Other
32
3
26
39
1. Treasury shares are included; however, voting rights of treasury shares cannot be exercised. 2. Novo Holdings A/S's registered address is Tuborg Havnevej 19, DK-2900 Hellerup, Denmark. 3. Split of shareholders is denoted according to the location of legal deposit-owners.
38View entire presentation